
Opinion|Videos|July 29, 2024
Suboptimal Treatment of Inflammatory Bowel Disease in Clinical Practice
Silvio Danese, MD, PhD; Bruce Sands, MD, and Jean-Frederic Colombel, MD highlight the common practice in many community settings of treating inflammatory bowel disease with corticosteroids, with or without 5-aminosalicylic acid, and cycling patients through this regimen for prolonged periods, while emphasizing the significant impact and toxicities associated with this treatment approach.
Advertisement
Episodes in this series

In many community practices, IBD is treated with corticosteroids with or without 5-ASA, and patients are cycled through this regimen for a long time. How does this approach impact long-term patient outcomes?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
New Antifibrotics Are Changing the Treatment Calculus in ILD
2
Q&A: Intensive LDL Lowering and Cardiovascular Prevention Strategies, With Lawrence Leiter, MD
3
2 Out of 3 Patients with Atopic Dermatitis Are Being Misdiagnosed
4
Evaluating Clinical and Real-World Evidence in Hypercortisolism
5























































































